The Lancet Haematology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial..
11:e891-e904.
2024
-
Risk of harm to people with haemophilia from the 2023 WHO Essential Medicines List.
11:e638-e640.
2024
-
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study.
11:e436-e447.
2024
-
Diversity, equity, and inclusion in ASH guidelines.
11:e317-e317.
2024
-
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
11:e15-e26.
2024
-
Thromboprophylaxis in paediatric acute lymphoblastic leukaemia.
11:e3-e5.
2024
-
Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021.
10:e713-e734.
2023
-
Superficial vein thrombosis in pregnancy: what we did not know could hurt our patients.
10:e313-e314.
2023
-
Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years.
9:e689-e697.
2022
-
Development of an international standard set of outcome measures for patients with venous thromboembolism: an International Consortium for Health Outcomes Measurement consensus recommendation.
9:e698-e706.
2022
-
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.
9:e594-e604.
2022
-
Vaccine-induced immune thrombotic thrombocytopenia.
9:e73-e80.
2022
-
All-trans retinoic acid for treating immune thrombocytopenia: new purpose for an old drug?.
8:e672-e673.
2021
-
Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care.
8:e756-e769.
2021
-
Mortality benefits of thromboprophylaxis.
7:e783-e783.
2020
-
Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis.
7:e746-e755.
2020
-
Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial.
7:e640-e648.
2020
-
Is venous thromboembolism a preventable cause of death?.
7:e555-e556.
2020
-
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis – Authors' reply.
7:e364-e365.
2020
-
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
7:e100-e111.
2020
-
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
7:e18-e27.
2020
-
Splanchnic vein thrombosis: what are the long-term risks?.
5:e431-e432.
2018
-
Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
5:e252-e260.
2018
-
Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial.
4:e544-e552.
2017
-
Evaluation of direct oral anticoagulants in superficial-vein thrombosis – Authors' reply.
4:e254-e255.
2017
-
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.
4:e105-e113.
2017
-
High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis.
3:e489-e496.
2016
-
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
3:e437-e445.
2016
-
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
3:e379-e387.
2016
-
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry.
3:e267-e275.
2016
-
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
3:E228-E236.
2016
-
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
3:e228-e236.
2016
-
Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study.
3:E246-E254.
2016
-
Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study.
3:e246-e254.
2016
-
Real life studies and good clinical practice – Authors' reply.
3:e160-e161.
2016
-
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
3:e12-e21.
2016
-
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study.
2:e474-e480.
2015
-
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.
2:e75-e81.
2015
-
Treating clots in cancer: moving closer to an answer?.
1:e6-e7.
2014
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)